Baker Brothers latest buys and sells

39 buys and sells in Baker Brothers's latest 13F filing, largest first. The largest is the addition to RVMD, $353.6M or 1.8% of the reported portfolio.

Moves
39
Combined size
$1.2B

Key facts

Moves
39
New positions
8
Complete sales
8
Largest move
RVMD, $353.6M
Latest filing
Aug 14, 2026
Baker Brothers ✕

From Baker Bros. Advisors's filing for (Q2 2026), filed , against the filing for Mar 31, 2026.

Baker Brothers: buys and sells, latest filings
#StockMoveSharesSizeOf portfolio
1Revolution Medicines IncRVMD▲ Added 20%+1.89M$353.6M1.77%
2Insmed IncINSM▲ Added 19%+1.38M$146.6M0.73%
3Edgewise Therapeutics IncEWTX▼ Reduced 44%−2.87M$116.8M0.59%
4Abivax SAABVX▼ Sold out—$97.5M0.49%
5Summit Therapeutics IncSMMT▼ Reduced 9.9%−3.61M$52.5M0.26%
6Spyre Therapeutics IncSYRE▼ Sold out—$50.4M0.25%
7IDEAYA Biosciences IncIDYA▲ Added 27%+1.06M$39.6M0.20%
8Faeth Therapeutics IncFTH▲ New+1.29M$32.2M0.16%
9Relay Therapeutics IncRLAY▲ Added 144%+1.67M$31.2M0.16%
10
Centessa Pharmaceuticals PLCno ticker on file
▼ Sold out—$26.6M0.13%
11Immunocore Holdings plcIMCR▼ Sold out—$22.1M0.11%
12Abcellera Biologics IncABCL▲ Added 9.0%+2.74M$21.5M0.11%
13Celldex Therapeutics IncCLDX▲ Added 78%+517.25K$19.2M0.10%
14Contineum Therapeutics IncCTNM▼ Sold out—$18.6M0.09%
15argenx SEARGX▼ Sold out—$18.4M0.09%
16Cytokinetics IncCYTK▲ New+211.27K$18M0.09%
17Intellia Therapeutics IncNTLA▲ New+930.23K$15.7M0.08%
18Immatics N.V.IMTX▼ Reduced 13%−1.41M$14.3M0.07%
19Parabilis Medicines IncPBLS▲ New+500K$13.7M0.07%
20Arcus Biosciences IncRCUS▲ Added 103%+429.2K$13.2M0.07%
21Compass Pathways PlcCMPS▼ Sold out—$13M0.06%
22Avalyn Pharma IncAVLN▲ New+350K$11.5M0.06%
23Pharvaris N VPHVS▼ Sold out—$10.6M0.05%
24Cerus CorpCERS▼ Reduced 36%−3.61M$10.6M0.05%
25Tango Therapeutics IncTNGX▲ New+333.33K$10.4M0.05%
26Avalo Therapeutics IncAVTX▲ New+550K$10.2M0.05%
27Jade Biosciences IncJBIO▼ Reduced 25%−410.8K$9.1M0.05%
28Viridian Therapeutics IncVRDN▲ Added 21%+411.3K$7.6M0.04%
29Verastem IncVSTM▲ Added 327%+1.91M$7.3M0.04%
30Roivant Sciences LtdROIV▼ Reduced 3.1%−150.9K$5.3M0.03%
31Incyte CorpINCY▲ Added 0.06%+18.45K$2.1M0.01%
32Design Therapeutics IncDSGN▲ Added 3.6%+92.57K$1.3M0.01%
33Immunome IncIMNM▲ New+55.31K$1.2M0.01%
34Immunovant IncIMVT▼ Reduced 0.4%−22.92K$883.3K0.00%
35Madrigal Pharmaceuticals IncMDGL▲ Added 0.07%+1.5K$805K0.00%
36Beone Medicines LtdONC▲ Added 0.03%+2.64K$752.2K0.00%
37Kiniksa Pharmaceuticals InternationalKNSA▲ Added 0.3%+8.48K$542.2K0.00%
38Acadia Pharmaceuticals IncACAD▲ Added 0.04%+17.16K$434.1K0.00%
39Denali Therapeutics IncDNLI▲ Added 0.07%+2.61K$67.2K0.00%

Questions and answers

What did Baker Brothers buy last quarter?

The largest purchases in the latest 13F filing: RVMD, $353.6M; INSM, $146.6M; IDYA, $39.6M; FTH, $32.2M; RLAY, $31.2M; ABCL, $21.5M.

What did Baker Brothers sell last quarter?

The largest sales in the latest 13F filing: EWTX, $116.8M; ABVX, $97.5M; SMMT, $52.5M; SYRE, $50.4M; Centessa Pharmaceuticals PLC, $26.6M; IMCR, $22.1M.

How is the size of a buy or sell worked out?

As the change in shares at the price the filing implies for the quarter's end (reported value divided by shares) — an estimate of the trade, not what was paid. A position sold out is sized at its value in the previous filing.

Learn

Cite this page

Funkfolio, “Baker Brothers: buys and sells, Q2 2026 13F”, data as of 14 August 2026. https://funkfolio.com/gurus/activity?investor=baker-brothers

Underlying data: SEC EDGAR, Form 13F-HR.

Source: SEC EDGAR, Form 13F-HR. A move is a change in share count between an investor's latest filing and the one before; a share split in between is allowed for where one is on record. Size is the shares bought or sold at the price the filing implies for the period end (reported value ÷ shares) — an estimate of the trade, not what was paid — and a position sold out is sized at its value in the previous filing. “Of portfolio” sets that size against the portfolio reported for the period. Only each investor's 150 largest positions and 50 largest exits are read. Filings appear up to 45 days after the quarter ends; none of this is advice.